Sanofi India Ltd
NSE:SANOFI

Watchlist Manager
Sanofi India Ltd Logo
Sanofi India Ltd
NSE:SANOFI
Watchlist
Price: 6 221 INR 1.3% Market Closed
Market Cap: 143.3B INR

Operating Margin
Sanofi India Ltd

24%
Current
24%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24%
=
Operating Profit
4.9B
/
Revenue
20.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
IN
Sanofi India Ltd
NSE:SANOFI
143.3B INR
24%
US
Eli Lilly and Co
NYSE:LLY
711.5B USD
40%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
371.5B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
45%
CH
Roche Holding AG
SIX:ROG
209.8B CHF
33%
CH
Novartis AG
SIX:NOVN
186.7B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP
24%
US
Merck & Co Inc
NYSE:MRK
194.1B USD
34%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
11%
US
Pfizer Inc
NYSE:PFE
132.7B USD
27%

Sanofi India Ltd
Glance View

Market Cap
143.3B INR
Industry
Pharmaceuticals

Sanofi India Ltd., a prominent name in the pharmaceutical landscape, operates as a subsidiary of Sanofi S.A., the global healthcare giant headquartered in France. Its roots in India trace back to the early 1950s when it began importing and distributing vaccines. Over the decades, Sanofi India has evolved into a comprehensive provider of high-quality drugs, contributing significantly to the nation’s healthcare ecosystem. The company focuses primarily on therapeutic segments such as diabetes, cardiovascular diseases, oncology, and vaccines, boasting a robust portfolio of prescription medicines and over-the-counter products. By leveraging a vast network of healthcare professionals and engaging in continuous clinical research and development, Sanofi India ensures its position at the forefront of medical innovation, adhering to a global strategy of patient-oriented solutions and a commitment to improving health outcomes. Sanofi India's revenue model revolves around its diversified product portfolio, addressing a spectrum of critical health areas. The company generates income through the sale of its flagship products, which include insulin for diabetes management, anti-allergy medications, and innovative therapies for rare diseases, among others. While the domestic market plays a crucial role in its financial framework, Sanofi India also taps into international markets, exporting its high-quality pharmaceutical products across borders. The profitability of the company is further bolstered by its commitment to research and development, enabling it to introduce new drugs and therapies, thus continually expanding its market share. By maintaining strong distribution channels and fostering collaborations with medical institutions and regulatory bodies, Sanofi India ensures its products reach a broad consumer base, perpetuating its growth trajectory in the competitive pharmaceutical scene.

SANOFI Intrinsic Value
3 436.2 INR
Overvaluation 45%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24%
=
Operating Profit
4.9B
/
Revenue
20.4B
What is the Operating Margin of Sanofi India Ltd?

Based on Sanofi India Ltd's most recent financial statements, the company has Operating Margin of 24%.

Back to Top